Table 4.
Serious adverse events | Cohort 1 + 2, N = 6 (%) | Cohort 3 + 4, N = 15 (%) |
---|---|---|
Intraductal proliferative breast lesion | 1 (16.7) | 0 (0) |
Macular hole | 0 (0) | 1 (6.7) |
Osteoarthritis | 1 (16.7) | 0 (0) |
Pneumonia | 1 (16.7) | 0 (0) |
Pneumothorax | 0 (0) | 1 (6.7) |
Urinary tract infection | 0 (0) | 1 (6.7) |